Talk:Patent expiry and biosimilars

Discussion page·2 threads·no archives

This is the discussion page for the article Patent expiry and biosimilars. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Impurities carry the applicationResolved

The analytical package rather than the clinical one being decisive for peptide generics is the point that connects this article to the rest of the wiki. — BiosimilarBoaz (talk) 09:50, 26 February 2026 (UTC)

And it is the same specificity argument as everywhere else, applied to a regulatory decision. ✓ Done — Chromatokid (talk) 13:25, 26 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Expiry does not change research supplyDone

Worth stating, since patent expiry is often discussed as though it legitimised research-chemical sale. It is a separate category question. — GreyMarketGreer (talk) 10:20, 19 June 2026 (UTC)

Linked to the status article, which carries the category framework. ✓ Done — ImportPolicyIggy (talk) 13:55, 19 June 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

This page was last edited on 19 June 2026, by ImportPolicyIggy. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).